Redwire Successfully Returns Third Batch of Pharmaceutical Drug Experiments to Earth
Redwire (NYSE: RDW) has successfully returned its third batch of pharmaceutical drug crystals from space to Earth. The samples include crystals studied by Eli Lilly and Company using Redwire's PIL-BOX platform. The research builds on a November 2023 investigation that showed insulin crystals grown in microgravity are larger and more ordered than Earth-grown ones.
The PIL-BOX system features an integrated microscope for analyzing crystallization in microgravity. Redwire has processed 16 PIL-BOX units to date and recently launched 12 more units on SpaceX-31 with new partners Bristol Myers Squibb and ExesaLibero Pharma, alongside Butler University. Previous investigations focused on treatments for cardiovascular disease, obesity, and diabetes.
Redwire (NYSE: RDW) ha recentemente riportato con successo il suo terzo lotto di cristalli di farmaci from dallo spazio sulla Terra. I campioni includono cristalli studiati da Eli Lilly and Company utilizzando la piattaforma PIL-BOX di Redwire. La ricerca si basa su un'indagine di novembre 2023 che ha dimostrato che i cristalli di insulina cresciuti in microgravità sono più grandi e più ordinati rispetto a quelli cresciuti sulla Terra.
Il sistema PIL-BOX presenta un microscopio integrato per analizzare la cristallizzazione in microgravità. Fino ad oggi, Redwire ha elaborato 16 unità PIL-BOX e ha recentemente lanciato altre 12 unità con SpaceX-31 insieme ai nuovi partner Bristol Myers Squibb e ExesaLibero Pharma, insieme alla Butler University. Le indagini precedenti si sono concentrate su trattamenti per malattie cardiovascolari, obesità e diabete.
Redwire (NYSE: RDW) ha devuelto con éxito su tercer lote de cristales de medicamentos del espacio a la Tierra. Las muestras incluyen cristales estudiados por Eli Lilly and Company utilizando la plataforma PIL-BOX de Redwire. La investigación se basa en un estudio de noviembre de 2023 que mostró que los cristales de insulina cultivados en microgravedad son más grandes y ordenados que los cultivados en la Tierra.
El sistema PIL-BOX cuenta con un microscopio integrado para analizar la cristalización en microgravedad. Hasta la fecha, Redwire ha procesado 16 unidades PIL-BOX y recientemente lanzó 12 unidades más en SpaceX-31 con nuevos socios Bristol Myers Squibb y ExesaLibero Pharma, junto con la Universidad de Butler. Las investigaciones anteriores se centraron en tratamientos para enfermedades cardiovasculares, obesidad y diabetes.
레드와이어 (NYSE: RDW)가 성공적으로 세 번째 약물 결정 배치를 우주에서 지구로 반환했습니다. 샘플에는 레드와이어의 PIL-BOX 플랫폼을 사용하여 엘리 릴리 앤 컴퍼니가 연구한 결정이 포함되어 있습니다. 이 연구는 2023년 11월에 발표된 결과를 기반으로 하며, 미세중력에서 자란 인슐린 결정이 지구에서 자란 결정보다 크고 더 정돈되어 있다는 사실을 보여줍니다.
PIL-BOX 시스템은 미세중력에서 결정화를 분석하기 위한 통합 현미경을 갖추고 있습니다. 현재까지 레드와이어는 16개의 PIL-BOX 유닛을 처리하였으며, 최근 스페이스X-31과 함께 브리스톨 마이어스 스큅과 엑세사리베로 파르마 및 버틀러 대학교와 함께 12개의 새로운 유닛을 발사했습니다. 이전 연구는 심혈관 질환, 비만 및 당뇨병 치료에 중점을 두었습니다.
Redwire (NYSE: RDW) a récemment réussi à rapatrier son troisième lot de cristaux de médicaments de l'espace vers la Terre. Les échantillons comprennent des cristaux étudiés par Eli Lilly and Company en utilisant la plateforme PIL-BOX de Redwire. La recherche s'appuie sur une enquête de novembre 2023 qui a montré que les cristaux d'insuline cultivés en microgravité sont plus grands et plus ordonnés que ceux cultivés sur Terre.
Le système PIL-BOX dispose d'un microscope intégré pour analyser la cristallisation en microgravité. À ce jour, Redwire a traité 16 unités PIL-BOX et a récemment lancé 12 unités supplémentaires sur SpaceX-31 avec de nouveaux partenaires, Bristol Myers Squibb et ExesaLibero Pharma, ainsi que l'Université de Butler. Les recherches précédentes se sont concentrées sur des traitements pour les maladies cardiovasculaires, l'obésité et le diabète.
Redwire (NYSE: RDW) hat erfolgreich seine dritte Charge von pharmazeutischen Kristallen aus dem Weltraum zur Erde zurückgebracht. Die Proben umfassen Kristalle, die von Eli Lilly and Company unter Verwendung der PIL-BOX-Plattform von Redwire untersucht wurden. Die Forschung basiert auf einer Untersuchung aus dem November 2023, die zeigte, dass Insulinkristalle, die in Mikroschwerkraft gewachsen sind, größer und geordneter sind als die auf der Erde gewachsenen.
Das PIL-BOX-System verfügt über ein integriertes Mikroskop zur Analyse der Kristallisation in Mikroschwerkraft. Bis heute hat Redwire 16 PIL-BOX-Einheiten verarbeitet und kürzlich 12 weitere Einheiten mit SpaceX-31 zusammen mit den neuen Partnern Bristol Myers Squibb und ExesaLibero Pharma sowie der Butler University gestartet. Frühere Untersuchungen konzentrierten sich auf Behandlungen für Herz-Kreislauf-Erkrankungen, Fettleibigkeit und Diabetes.
- Successful completion of third batch of space-grown pharmaceutical crystals
- Demonstrated superior crystal growth in microgravity compared to Earth-based production
- Expansion of partnership network to include Bristol Myers Squibb and ExesaLibero Pharma
- Successfully processed 16 PIL-BOX units with 12 more recently launched
- None.
Insights
The successful return of pharmaceutical crystals grown in space represents significant progress in Redwire's commercial space-based drug research program. The collaboration with Eli Lilly has yielded promising results, particularly in insulin crystallization, showing superior quality compared to Earth-grown crystals. With 16 PIL-BOX units processed and 12 more recently launched, Redwire is demonstrating scalable capabilities in space-based pharmaceutical research.
The expansion of partnerships to include Bristol Myers Squibb and ExesaLibero Pharma indicates growing industry confidence in space-based drug development. The PIL-BOX platform's integrated microscope enables real-time analysis of crystallization processes, providing valuable data for drug development. The focus on treatments for cardiovascular disease, obesity and diabetes targets major market opportunities in the pharmaceutical industry.
This development strengthens Redwire's position in the commercial space sector, particularly in the lucrative pharmaceutical research market. The successful demonstration of repeatable results and expansion of partnerships with major pharmaceutical companies like Eli Lilly and Bristol Myers Squibb validates their business model and technology platform. The PIL-BOX system's proven track record could lead to increased demand and revenue streams from pharmaceutical research contracts.
The company's ability to scale operations and maintain quality while expanding its client base suggests potential for significant growth in this segment. The focus on chronic disease treatments represents access to multi-billion dollar markets, though revenue impact will depend on successful drug development outcomes from these experiments.
Redwire and Lilly launched a research investigation in November 2023 that successfully demonstrated that insulin crystals grown in microgravity are larger and more ordered than those grown on Earth. Building upon this success, Lilly researchers will use the findings from this second investigation to expand their understanding of crystal formation and how they can impact drug discovery and development.
“Redwire has continued to build momentum with our pharmaceutical research capabilities as we identify critical new targets for breakthrough research and increase throughput of drug manufacturing experiments in space using PIL-BOX,” said John Vellinger, President of In-Space Industries at Redwire. “We are grateful for our strong partnership with Eli Lilly and Company and other researchers, as well as the support from the ISS
Another investigation that returned to Earth successfully crystallized the same insulin experiments flown as part of a previous investigation to demonstrate consistent, repeatable results. The PIL-BOX system used in these investigations includes an integrated microscope for in-situ analysis of the crystallization process in microgravity. This analytical tool provides researchers with insight and data that can be used in drug discovery, developing new drugs, and improving existing products.
The return of these newest crystals marks the latest in a growing series of investigations leveraging PIL-BOX. Redwire has successfully processed 16 PIL-BOX units to date. Redwire recently launched 12 more PIL-BOX units onboard the SpaceX-31 cargo resupply mission to the ISS with new partners Bristol Myers Squibb and ExesaLibero Pharma, along with a second spaceflight investigation with Butler University. Previous PIL-BOX investigations have focused on various crystal molecules for treatments of cardiovascular disease, obesity, and diabetes.
About Redwire
Redwire Corporation (NYSE:RDW) is a global space infrastructure and innovation company enabling civil, commercial, and national security programs. Redwire’s proven and reliable capabilities include avionics, sensors, power solutions, critical structures, mechanisms, radio frequency systems, platforms, missions, and microgravity payloads. Redwire combines decades of flight heritage and proven experience with an agile and innovative culture. Redwire’s approximately 700 employees working from 16 facilities located throughout
View source version on businesswire.com: https://www.businesswire.com/news/home/20241106647012/en/
Media Contact:
Emily Devine
Emily.Devine@redwirespace.com
+1 305-632-9137
OR
Investors:
investorrelations@redwirespace.com
+1 904-425-1431
Source: Redwire Corporation
FAQ
What was the outcome of Redwire's (RDW) third batch of pharmaceutical experiments in space?
How many PIL-BOX units has Redwire (RDW) processed in space to date?
What were the results of Redwire's (RDW) November 2023 insulin crystal investigation?
Who are Redwire's (RDW) new partners for the PIL-BOX space experiments?
